Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 16, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 530,000 ordinary shares of 25 pence each.
- Purchase Price: 1,489.61 pence per share.
- Treasury Holdings: 252,777,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,753,071,084 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 530,000 shares on February 16, 2007. These shares are intended to be held in Treasury. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,753,071,084) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (252,777,678) for accurate share capital analysis.
- Note that this filing is a transactional report and does not contain quarterly or annual financial performance data.